Medical Cannabis Market Size, Share, Growth, and Industry Analysis, By Type (Tetrahydrocannabinol (THC),Cannabidiol (CBD)), By Application (Pain,Arthritis,Neurological Disease (Epilepsy, Multiple Sclerosis and Other Neurological Applications),Others), Regional Insights and Forecast to 2035

Medical Cannabis Market Overview

The global Medical Cannabis Market is forecast to expand from USD 50041.24 million in 2026 to USD 56346.43 million in 2027, and is expected to reach USD 145603.42 million by 2035, growing at a CAGR of 12.6% over the forecast period.

The Medical Cannabis Market is developing as regulated medical programs, clinical research, physician awareness, pharmaceutical development, and standardized cannabinoid formulations expand across permitted jurisdictions. Cannabidiol (CBD) accounts for approximately 57% market share within the supplied type segmentation, supported by its presence across regulated therapeutic and pharmaceutical applications. Market development increasingly emphasizes standardized composition, controlled manufacturing, laboratory testing, pharmaceutical-grade quality systems, traceability, and clearly defined administration formats. Regulatory frameworks remain central to commercial development because authorization, prescription requirements, permitted indications, cultivation controls, and distribution practices differ substantially between individual countries and jurisdictions.

The United States represents an important but structurally complex medical cannabis environment because regulatory conditions vary between federal and state frameworks. Pain applications account for approximately 39% market share within the modeled application structure, reflecting substantial clinical interest in cannabinoid-based approaches within permitted medical programs. Market participants increasingly emphasize controlled production, laboratory verification, accurate cannabinoid composition, patient-oriented formulations, and healthcare-professional engagement. Continued research into therapeutic applications is influencing product development, while manufacturers must navigate requirements covering cultivation, processing, testing, labeling, dispensing, and patient access according to the rules applicable within each jurisdiction.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Pain applications lead with approximately 39% market share as regulated medical programs continue supporting cannabinoid-based therapeutic use across permitted patient populations.
• Major Market Restraint: Arthritis represents approximately 18% market share as variable regulatory frameworks and differing clinical adoption conditions influence access across therapeutic applications.
• Emerging Trends: Neurological Disease applications account for approximately 28% market share as pharmaceutical research increasingly examines standardized cannabinoid formulations for neurological indications.
• Regional Leadership: North America leads with approximately 42% market share, supported by established medical programs, product availability, research activity, and regulated patient access.
• Competitive Landscape: The supplied competitive landscape includes 11 companies participating across cultivation, cannabinoid processing, pharmaceutical development, formulation, testing, and regulated medical distribution.
• Market Segmentation: Cannabidiol (CBD) leads the supplied type segmentation with approximately 57% market share, supported by established medical and pharmaceutical applications.
• Recent Development: Five major development themes characterize 2026, emphasizing clinical research, standardized formulations, manufacturing quality, pharmaceutical development, and regulated patient access.

Medical Cannabis Market Latest Trends

Neurological Disease applications, including Epilepsy, Multiple Sclerosis and Other Neurological Applications, represent approximately 28% market share and remain an important area for cannabinoid-focused pharmaceutical research. Development activity increasingly emphasizes standardized formulations with measurable cannabinoid concentrations rather than inconsistent or poorly characterized preparations. Manufacturers are strengthening analytical testing, batch consistency, contaminant controls, extraction processes, and pharmaceutical-quality production systems. Research-oriented development is also encouraging closer interaction among manufacturers, clinicians, researchers, and regulatory authorities as companies seek evidence supporting specific formulations and administration approaches within legally permitted medical frameworks.

Tetrahydrocannabinol (THC) accounts for approximately 43% market share within the supplied type segmentation and remains important in medical programs where THC-containing products are legally authorized. Product development is moving toward controlled concentrations, reproducible formulations, accurate labeling, and administration formats designed for more predictable patient use. Another major trend is increased differentiation between medical products and broader cannabis categories, with medical suppliers emphasizing physician oversight, testing standards, manufacturing controls, and documented product specifications. This transition supports greater professionalization across the industry while increasing the technical and regulatory requirements faced by participating companies.

Medical Cannabis Market Dynamics

DRIVER

"Regulated therapeutic adoption supports medical cannabis demand."

Pain applications account for approximately 39% market share and represent the largest supplied therapeutic category, supporting demand within jurisdictions where medical cannabis is authorized for appropriate patients. Chronic and persistent pain conditions have encouraged clinical interest in cannabinoid-based treatment approaches, although access depends on local medical regulations, prescribing frameworks, and professional assessment. Market growth is increasingly connected with structured medical programs that establish patient eligibility, product standards, dispensing requirements, and healthcare oversight. Manufacturers serving these programs focus on reliable cannabinoid composition and controlled production to meet evolving expectations surrounding medical-use products.

Greater professionalization of medical cannabis supply chains is another important driver. Companies are investing in cultivation controls, extraction technology, formulation capabilities, laboratory testing, manufacturing consistency, and traceability to improve product reliability. Medical practitioners and patients require clear information regarding cannabinoid composition and administration, increasing the importance of standardized labeling and product specifications. As regulated programs mature, suppliers capable of maintaining repeatable quality and documented manufacturing procedures can participate more effectively in healthcare-oriented channels. Research activity additionally supports development by improving understanding of potential applications and formulation requirements.

RESTRAINT

"Regulatory fragmentation limits consistent market access."

Arthritis accounts for approximately 18% market share within the supplied application segmentation, but broader therapeutic adoption remains influenced by differences in medical cannabis regulations and clinical practice. Some jurisdictions maintain established medical programs, while others impose substantial restrictions or do not permit comparable access. Requirements covering physician authorization, patient eligibility, permitted cannabinoid concentrations, cultivation, processing, importation, dispensing, and product formats can differ considerably. This fragmentation increases compliance costs and makes it difficult for manufacturers to establish uniform products and commercial strategies across multiple geographic markets.

Clinical evidence requirements also create constraints for companies seeking greater integration with conventional healthcare and pharmaceutical systems. Different cannabinoid formulations cannot automatically be treated as equivalent because composition, dosage form, concentration, manufacturing process, and administration method can influence therapeutic evaluation. Companies therefore need investment in research, analytical characterization, quality systems, and regulatory documentation. Medical professionals may also require stronger evidence and clearer treatment protocols before adopting particular products broadly. These factors can lengthen development timelines and increase the resources required to establish medically differentiated cannabinoid products.

OPPORTUNITY

"Standardized formulations create pharmaceutical development opportunities."

Cannabidiol (CBD) represents approximately 57% market share within the supplied type segmentation and provides opportunities for pharmaceutical research, standardized formulation development, and regulated therapeutic applications. Companies can invest in products with clearly defined cannabinoid concentrations, controlled excipient systems, validated manufacturing processes, and reproducible administration characteristics. Pharmaceutical-style development can strengthen differentiation by moving beyond basic extracts toward formulations designed around specific product specifications. Analytical testing and stability evaluation are also becoming more important as manufacturers seek greater consistency throughout shelf life and across production batches.

Opportunities also exist in clinical research and evidence generation for the supplied therapeutic categories. Manufacturers can collaborate within appropriate regulatory frameworks to evaluate cannabinoid formulations, administration methods, safety characteristics, and patient outcomes. Improved evidence can support more informed healthcare decision-making and help companies identify formulations suitable for further development. Investment in extraction technology, purification, formulation science, testing laboratories, and controlled manufacturing can additionally create intellectual-property and technical differentiation. Companies with strong research capabilities may be better positioned to participate as medical cannabis becomes increasingly integrated with regulated pharmaceutical-development practices.

CHALLENGE

"Product consistency remains essential for clinical acceptance."

Others account for approximately 15% market share within the supplied application segmentation and illustrate the diverse therapeutic areas in which medical cannabis may be evaluated under appropriate regulatory and clinical conditions. This diversity creates a challenge because products developed for different applications can require distinct cannabinoid profiles, formulations, administration methods, and evidence. Manufacturers need to avoid treating medical cannabis as a uniform product category and instead establish precise specifications for individual formulations. Maintaining consistency from raw material through finished product is particularly important when products are intended for healthcare-oriented use.

Quality control across cultivation, extraction, formulation, packaging, storage, and distribution presents another substantial challenge. Variations in raw botanical materials can complicate efforts to achieve consistent finished-product composition unless companies use controlled processes and rigorous analytical testing. Manufacturers must also monitor contaminants, stability, cannabinoid concentrations, and batch-to-batch reproducibility according to applicable requirements. As healthcare systems place greater emphasis on standardized products, companies unable to demonstrate dependable quality may face barriers to professional acceptance. Strong manufacturing controls and transparent product characterization therefore remain fundamental to sustainable participation in regulated medical cannabis markets.

Medical Cannabis Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Type

Tetrahydrocannabinol (THC): Tetrahydrocannabinol (THC) accounts for approximately 43% market share within the supplied type segmentation and remains important across regulated medical cannabis programs where THC-containing formulations are legally authorized. Demand is influenced by physician-supervised use, permitted therapeutic applications, product availability, and jurisdiction-specific regulations. Manufacturers increasingly emphasize controlled concentrations, accurate labeling, batch consistency, laboratory testing, and standardized administration formats to improve predictability and support healthcare-oriented use within approved medical frameworks.

Development of THC-based medical products requires careful management of cultivation, extraction, purification, formulation, testing, packaging, and distribution. Manufacturers must maintain reliable cannabinoid specifications while addressing regulatory requirements that can differ substantially between jurisdictions. Pharmaceutical-oriented companies are increasingly applying structured quality systems and analytical methods to improve reproducibility across production batches. Research into formulation characteristics and administration methods also remains important as developers seek products that provide clearly characterized composition and can be evaluated systematically within appropriate clinical and regulatory environments.

Cannabidiol (CBD): Cannabidiol (CBD) leads the supplied type segmentation with approximately 57% market share, supported by established medical interest, pharmaceutical development, and research across regulated therapeutic applications. CBD-based products increasingly emphasize defined concentrations, controlled manufacturing, analytical verification, and standardized formulations. The segment benefits from continuing investigation into cannabinoid-based therapeutic approaches, although authorization and permitted applications remain dependent on individual regulatory jurisdictions. Companies with pharmaceutical development capabilities are focusing on formulation science, quality assurance, stability, and reproducible product characteristics.

CBD product development increasingly moves beyond basic extracts toward formulations designed around measurable specifications and controlled administration. Manufacturers are investing in purification technologies, contaminant testing, stability evaluation, dosage-form development, and batch documentation to strengthen product reliability. Regulatory pathways can differ according to whether a CBD product is classified within a medical cannabis program or treated through a pharmaceutical framework. This creates opportunities for technically capable suppliers while requiring careful regulatory planning throughout research, manufacturing, product registration, and commercial distribution.

By Application

Pain: Pain represents approximately 39% market share and is the largest application within the supplied Medical Cannabis Market segmentation. Demand is associated with regulated medical programs in which appropriate patients may receive cannabinoid-based products under applicable healthcare requirements. Persistent and chronic pain conditions have encouraged continuing clinical interest in cannabinoids, although treatment decisions depend on individual patient circumstances and professional medical assessment. Manufacturers serving this application increasingly emphasize standardized products that provide clearly characterized cannabinoid composition and consistent manufacturing quality.

Product development for pain applications is becoming more technically structured as companies evaluate cannabinoid concentrations, administration formats, formulation characteristics, and product consistency. Healthcare-oriented suppliers need reliable analytical testing and manufacturing controls because poorly characterized products create challenges for professional use. Clinical research remains important for understanding potential benefits, limitations, safety considerations, and appropriate administration approaches. Companies capable of combining standardized production with evidence development can participate more effectively as regulated medical cannabis programs become increasingly formalized.

Arthritis: Arthritis accounts for approximately 18% market share within the supplied application structure and represents an area of continuing interest for cannabinoid-based medical products. Patients experiencing persistent symptoms may seek treatment options within jurisdictions where medical cannabis is legally available and considered appropriate by healthcare professionals. Market participation nevertheless depends on regulatory authorization, clinical practice, patient eligibility, and available evidence. Manufacturers must avoid generalized product positioning and instead develop formulations with clearly defined composition and appropriate quality controls.

Research and formulation development remain important for this application because arthritis encompasses different conditions and patient requirements. Manufacturers seeking healthcare-oriented positioning increasingly focus on standardized cannabinoid profiles, controlled production processes, stability, and analytical characterization. Medical adoption can also depend on healthcare-professional familiarity and evidence regarding specific formulations rather than the cannabis category broadly. Consequently, companies investing in product characterization and structured research may be better positioned to support informed use within regulated medical settings.

Neurological Disease (Epilepsy, Multiple Sclerosis and Other Neurological Applications): Neurological Disease applications account for approximately 28% market share and represent an important area for pharmaceutical and clinical research involving cannabinoid-based formulations. The segment includes Epilepsy, Multiple Sclerosis and Other Neurological Applications, creating diverse development requirements rather than a single uniform therapeutic market. Companies increasingly focus on precisely characterized products, reproducible cannabinoid concentrations, controlled administration formats, and evidence generation appropriate to specific neurological applications.

Development within neurological applications requires particularly rigorous attention to clinical evidence, formulation consistency, patient safety, and healthcare oversight. Manufacturers may need pharmaceutical-quality production systems and extensive analytical characterization when products are intended for structured medical use. Research programs can evaluate individual cannabinoid compositions and administration methods rather than assuming equivalent effects across different formulations. This evidence-oriented approach is encouraging stronger integration between cannabinoid science, pharmaceutical development, laboratory testing, and regulated clinical evaluation.

Others: Others represent approximately 15% market share and encompass the remaining medical applications within the supplied segmentation. This category illustrates the breadth of research interest surrounding cannabinoids while also highlighting the need for application-specific evidence. Potential medical use cannot be generalized across conditions because product composition, administration, patient characteristics, and clinical requirements can differ substantially. Companies exploring additional applications therefore need structured development programs aligned with applicable regulatory and medical standards.

The diversity of this application category creates opportunities for research-led companies while increasing technical and regulatory complexity. Manufacturers must determine appropriate cannabinoid specifications, formulation approaches, analytical methods, and quality requirements for individual development programs. Evidence generation is particularly important when moving into less established therapeutic areas because healthcare adoption depends on credible information concerning safety and potential clinical utility. Companies with integrated research, formulation, manufacturing, and regulatory capabilities can manage these requirements more systematically.

Medical Cannabis Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America leads the Medical Cannabis Market with approximately 42% market share, supported by established medical cannabis programs across multiple jurisdictions, substantial commercial infrastructure, clinical research activity, and growing availability of standardized cannabinoid products. The United States and Canada contribute to regional development through different regulatory structures, requiring companies to maintain jurisdiction-specific strategies. Product quality, testing, controlled manufacturing, and healthcare engagement are increasingly important as the market develops beyond early-stage commercialization.

Regional manufacturers are strengthening extraction, purification, formulation, analytical testing, and pharmaceutical-development capabilities to improve product differentiation. The United States remains structurally complex because medical cannabis regulations differ between federal and state frameworks, while Canada operates within its own national regulatory system. Companies therefore need sophisticated compliance strategies rather than a uniform North American model. Research partnerships and standardized product development continue to support the transition toward more evidence-oriented medical cannabinoid applications.

Europe

Europe accounts for approximately 27% market share, supported by expanding medical cannabis frameworks, pharmaceutical research, controlled patient-access programs, and increasing interest in standardized cannabinoid formulations. Regulatory approaches vary considerably between European countries, creating differences in prescription pathways, reimbursement conditions, permitted products, cultivation rules, and import requirements. Companies entering multiple European markets consequently require detailed regulatory planning and product strategies adapted to individual national healthcare systems.

European market development increasingly emphasizes pharmaceutical-quality standards, evidence generation, controlled manufacturing, and dependable cannabinoid specifications. Suppliers seeking participation in medical channels need robust documentation and quality-management systems capable of meeting demanding regulatory expectations. Cross-border supply can also require coordination of importation, distribution, storage, and product authorization requirements. Companies with pharmaceutical expertise and strong compliance capabilities can address these conditions while supporting healthcare professionals with more standardized and clearly characterized products.

Asia-Pacific

Asia-Pacific represents approximately 18% market share, with development shaped by substantial differences in medical cannabis policies between individual countries. Some jurisdictions have established or evolving frameworks for specific cannabinoid-based medical products, while others maintain significant restrictions. These differences require manufacturers to assess each market independently and avoid assuming that regulatory acceptance in one country translates into access elsewhere. Research activity and pharmaceutical development are important pathways for regional market participation.

Opportunities within Asia-Pacific increasingly center on controlled medical applications, pharmaceutical formulations, clinical research, and compliant cannabinoid production where permitted. Companies need detailed understanding of import rules, product classification, prescription requirements, manufacturing standards, and patient-access mechanisms. Regulatory caution across parts of the region increases the importance of evidence-based development and transparent product characterization. Manufacturers with strong scientific and regulatory capabilities are better equipped to navigate this diverse environment while adapting products to individual national requirements.

Middle East and Africa

Middle East and Africa accounts for approximately 6% market share, reflecting an emerging but highly varied medical cannabis environment. Regulatory acceptance differs substantially between countries, with market activity generally concentrated where specific medical, cultivation, pharmaceutical, or research frameworks permit cannabinoid-related operations. Companies evaluating the region need careful jurisdiction-level assessment because legal conditions, permitted products, import requirements, and patient-access mechanisms cannot be generalized across the broader geographic area.

Development opportunities are associated primarily with regulated medical programs, pharmaceutical research, controlled cultivation where authorized, and standardized product supply. Quality assurance and regulatory documentation remain essential because emerging markets often establish detailed requirements as frameworks develop. International suppliers may need local partnerships and specialized distribution arrangements to navigate importation and healthcare channels. Long-term participation depends on compliance, product quality, clinical credibility, and the ability to respond as national regulatory structures evolve.

Rest of World

Rest of World represents approximately 7% market share and includes additional jurisdictions at different stages of medical cannabis regulation, clinical research, and commercial development. Some markets permit specific cannabinoid medicines or controlled patient-access programs, while others maintain more restrictive policies. Commercial opportunities therefore depend strongly on national legislation, healthcare frameworks, product classification, and permitted distribution mechanisms rather than a uniform global approach.

Companies entering these markets require flexible regulatory strategies and standardized manufacturing capabilities that can be adapted to local requirements. Pharmaceutical-quality products, laboratory testing, documented cannabinoid composition, and reliable supply-chain controls can support participation where medical access is authorized. Research collaboration may also provide an entry pathway in jurisdictions where broader commercial frameworks remain limited. Successful participation depends on maintaining scientific credibility and regulatory compliance while responding carefully to changing national policies.

List of Top Medical Cannabis Market Companies

• Canopy Growth Corporation
• BOL Pharma
• Aurora Cannabis, Inc
• Aphria, Inc
• GW Pharmaceuticals, plc
• Medreleaf Corporation
• Insys Therapeutics, Inc
• Medipharm Labs
• MGC Pharmaceuticals Limited
• Medical Marijuana Inc
• Tilray

Top Two Companies With Highest Market Share

• Canopy Growth Corporation: Holds approximately 14% market share, supported by established cannabinoid operations, product development capabilities, regulated-market participation, and extensive production infrastructure.
• Aurora Cannabis, Inc: Holds approximately 11% market share, supported by cultivation capabilities, medical cannabis operations, product diversification, international participation, and regulated distribution experience.

Investment Analysis and Opportunities

Investment activity in the Medical Cannabis Market increasingly emphasizes pharmaceutical research, standardized cultivation, extraction technology, formulation development, laboratory testing, quality assurance, and regulated manufacturing infrastructure. Cannabidiol (CBD) accounts for approximately 57% market share within the supplied type segmentation, creating significant opportunities for companies developing clearly characterized cannabinoid formulations and healthcare-oriented products. Investment priorities include purification technology, analytical laboratories, stability testing, controlled manufacturing environments, batch documentation, and traceability systems. Companies are also allocating resources toward clinical research and regulatory capabilities that can support evidence generation and structured product development across permitted medical applications.

North America accounts for approximately 42% market share and remains an important investment environment because of established medical cannabis programs, research infrastructure, product availability, and commercial participation. Opportunities extend beyond cultivation toward higher-value activities including pharmaceutical formulation, cannabinoid isolation, clinical development, manufacturing technology, and quality-control services. Investors and operators increasingly assess businesses according to production efficiency, regulatory positioning, intellectual property, scientific capabilities, and sustainable patient-oriented demand rather than cultivation capacity alone. Companies with integrated research, manufacturing, testing, and compliance capabilities can address the industry's transition toward more standardized and evidence-driven medical products.

New Product Development

New product development is increasingly centered on standardized cannabinoid formulations designed to provide measurable composition, controlled administration, consistent manufacturing, and dependable product characteristics. Tetrahydrocannabinol (THC) represents approximately 43% market share within the supplied type segmentation and remains relevant to product development where THC-containing medical formulations are permitted. Developers are focusing on controlled concentrations, formulation stability, accurate labeling, improved analytical characterization, and reproducible manufacturing. Product-development programs increasingly incorporate quality requirements from early research stages so formulations can be evaluated systematically rather than relying on broadly characterized botanical preparations with substantial compositional variability.

Neurological Disease applications, including Epilepsy, Multiple Sclerosis and Other Neurological Applications, account for approximately 28% market share and continue encouraging research-oriented product development. Pharmaceutical developers are evaluating cannabinoid composition, administration formats, formulation characteristics, stability, and manufacturing consistency for specific neurological applications. New products increasingly require supporting analytical and clinical information appropriate to their intended use and regulatory pathway. Manufacturers capable of integrating formulation science, controlled production, laboratory testing, clinical research, and regulatory documentation can create differentiated products while improving the consistency expected from cannabinoid-based therapies intended for structured healthcare environments.

Five Recent Developments

• January 2026 – Clinical Research Programs Gain Greater Focus: Medical cannabis companies increased emphasis on structured research programs evaluating standardized cannabinoid formulations, therapeutic applications, administration approaches, and patient-oriented product characteristics.
• March 2026 – Standardized Formulations Receive Development Priority: Manufacturers strengthened formulation programs focused on measurable cannabinoid composition, batch consistency, stability, controlled administration, and more clearly characterized medical products.
• May 2026 – Manufacturing Quality Systems Expand Further: Producers continued improving cultivation controls, extraction processes, analytical testing, contaminant management, traceability, and manufacturing documentation to support regulated medical applications.
• June 2026 – Pharmaceutical Development Capabilities Strengthen: Market participants expanded research, formulation, testing, and regulatory capabilities as medical cannabis development became increasingly aligned with evidence-oriented pharmaceutical practices.
• July 2026 – Pain Applications Maintain Market Leadership: Pain applications, representing approximately 39% market share, remained the largest supplied therapeutic category as regulated programs continued supporting appropriate cannabinoid-based medical use.

Report Coverage of Medical Cannabis Market

The Medical Cannabis Market report provides detailed coverage of market conditions, growth drivers, restraints, opportunities, challenges, emerging trends, segmentation, regional performance, competitive participation, investment priorities, new product development, and recent industry activity. Type analysis covers Tetrahydrocannabinol (THC) and Cannabidiol (CBD), while application analysis includes Pain, Arthritis, Neurological Disease (Epilepsy, Multiple Sclerosis and Other Neurological Applications), and Others. The report examines regulated medical access, cannabinoid formulation, cultivation controls, extraction, purification, laboratory testing, pharmaceutical manufacturing, clinical research, quality assurance, product stability, traceability, healthcare engagement, and the regulatory factors influencing commercial participation.

Regional coverage includes North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of World, while competitive coverage evaluates all 11 supplied companies across medical cannabis operations, cannabinoid processing, pharmaceutical development, formulation capabilities, manufacturing quality, research participation, and regulated-market presence. The report additionally examines investment opportunities associated with standardized production, analytical laboratories, clinical evidence, extraction technology, formulation science, regulatory capabilities, and pharmaceutical-oriented product development. Coverage provides a structured assessment of how therapeutic demand, scientific research, product consistency, regional regulation, healthcare acceptance, manufacturing standards, and competitive capabilities influence development across the Medical Cannabis Market.

Medical Cannabis Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 50041.24 Million in 2026
Market Size Value By	USD 145603.42 Million by 2035
Growth Rate	CAGR of 12.6% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Tetrahydrocannabinol (THC) Cannabidiol (CBD) By Application : Pain Arthritis Neurological Disease (Epilepsy Multiple Sclerosis and Other Neurological Applications) Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample